查詢結果分析
來源資料
相關文獻
- Long-term Results of a Pars Plana Vitrectomy for Complications of Proliferative Diabetic Retinopathy
- Evaluation of the Pain-Relieving Effect of Carbamazepine (Tegretol[feb9]) during Panretinal Photocoagulation
- HELLP Syndrome with Antepartum Pulmonary Edema--A Case Report
- Ephedrine-Induced Complete Atrioventricular Block with Ventricular Asystole during Rapid Concomitant Phenytoin Infusion: A Case Report
- Epiglottic Hematoma Secondary to Endotracheal Intubation
- 臺灣地區慢性脊髓損傷病患排尿處置之調查報告
- 小兒使用TPN引起的併發症
- 淺談糖尿病及其併發症
- 難忘的病人--民俗療法之併發症
- Clinical Experience with Ventricular Endomyocardial Biopsy in Chinese Heart Transplant Patients: A Four-Year Survey of 1,208 Consecutive Procedures
頁籤選單縮合
題 名 | Long-term Results of a Pars Plana Vitrectomy for Complications of Proliferative Diabetic Retinopathy=增殖型糖尿病視網膜病變施行坦部玻璃體切除術後之長期追蹤成果 |
---|---|
作 者 | 鄭成國; 王廷文; | 書刊名 | 輔仁醫學期刊 |
卷 期 | 4:2 民95.06 |
頁 次 | 頁53-60 |
分類號 | 416.745 |
關鍵詞 | 視力結果; 併發症; 坦部玻璃體切除術; 增殖性糖尿病視網膜病變; 纖維血管增生; 牽引性視網膜剝離; Visual outcome; Pars plana vitrectomy; Proliferative diabetic retinopathy; Vitreous hemorrhage; Fibrovascular proliferation; Tractional retinal detachment; |
語 文 | 英文(English) |
中文摘要 | 背景與目的:坦部玻璃體切除術是對於增殖性糖尿病視網膜病變所引起的嚴重併發症的一項最重要的治療方法。本研究回顧我們過去八年針對增殖性糖尿病視網膜病變所引起的嚴重併發症施行坦部玻璃體切除術後,在追蹤6 個月,12 個月,18 個月及24 個月時的視力結果及產生之併發症。方法:回溯性報導233 隻眼睛(192 個病人)罹患增殖型糖尿病視網膜病變,施行坦部玻璃體切除術後的成果。結果:最佳矯正視力改善或不變者,在術後6 個月,12 個月,18 個月及24 個月分別有150/169 個眼睛(88.8%),109/128 個眼睛(85.1%),91/108 個眼睛(84.3%)及60/77 個眼睛(77.9%)。在完成術後24 個月追蹤期的77 個眼睛之中,其最佳矯正視力有23 個眼睛(30%) < 1/60,31 個眼睛(40%)介於1/60 至6/60 之間,另外23 個眼睛(30%) 6/30,此結果明顯優於術前視力(p < 0.01,chi-square test)。術後最主要的併發症有白內障(42.0%),玻璃體出血(23.2%),新生血管性青光眼(8.2%),脈絡膜剝離(7.7%),黃斑部病變(3.9%),牽引性視網膜剝離(3.0%)及視網膜上薄膜(3.0%)。結論:坦部玻璃體切除術可有效改善糖尿病視網膜病變所產生之併發症患者的視力。此結果可有效的持續達2 年之久。 |
英文摘要 | Background and Purpose: A pars plana vitrectomy (PPV) is a very important method for the treatment of severe complications of proliferative diabetic retinopathy. This report reviews our last 8 years of experience in using PPV for treating complications of diabetic retinopathy, with the purpose of delineating the visual outcomes and complications of PPV after 6, 12, 18, and 24months of follow-up. Methods: The records of 233 eyes (of 192 patients) with proliferative diabetic retinopathy that had undergone pars plana vitrectomy were retrospectively reviewed. Results: Postoperative best-corrected visual acuity improved or was maintained in 150 of 169 (88.8%), 109 of 128 (85.1%), 91 of 108 (84.3%), and 60 of 77 (77.9%) eyes at 6, 12, 18, and 24 months of follow-up, respectively. In the 77 eyes that completed 24months of follow-up after surgery, 23 eyes (30%) had a best-corrected vision of < 1/60, 31 eyes (40%) had vision of 1/60~6/60, and 23 eyes (30%) had vision of 6/30, which was significantly better than the preoperative vision (p<0.01, Chi-squared test). The major postoperative complications included cataracts (42.0%), vitreous hemorrhage (23.2%), neovascular glaucoma (8.2%), choroidal detachment (7.7%), maculopathy (3.9%), tractional retinal detachment (3.0%), and epiretinal membrane (3.0%). Conclusions: A pars plana vitrectomy is an effective method for improving the visual outcomes of patients with complications of severe diabetic retinopathy. The favorable results of this procedure can be maintained for a period of up to 2 years. |
本系統中英文摘要資訊取自各篇刊載內容。